We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

CRISPR Therapeutics AG (NASDAQ:CRSP) has reported that its CEO, Samarth Kulkarni, sold a total of $1,449,628 worth of company stock, according to a recent SEC filing. The... ZUG, Switzerland ...

developed with CRISPR Therapeutics (NASDAQ:CRSP). The deal comes after the National Institute for Health and Care Excellence (NICE), which sets the drug policy for the NHS, endorsed Casgevy’s ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...